INMB
INmune Bio Inc
1.90$
-3.6%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 72.7% | 70.1% | 63.7% | 67.7% | 67.9% | 57.3% | 55.4% | 95.6% | 91.9% | 92.4% | 88.4% | 88.7% | |
| 66.7% | 62.9% | 55.5% | 59.2% | 63.6% | 52.9% | 51.2% | 88.6% | 83.1% | 76.5% | 82.7% | 68.6% | |
| 66.7% | 62.9% | 55.5% | 59.2% | 63.6% | 52.9% | 51.2% | 88.6% | 83.1% | 76.5% | 82.7% | 68.6% | |
| 3.6% | 4.3% | 5.7% | 6.5% | 2.7% | 3.6% | 3.7% | 5.7% | 7.4% | 14.0% | 3.0% | 17.8% | |
| – | – | – | – | -2.7% | – | – | – | – | – | – | – | |
| 26.3% | 29.0% | 35.3% | 31.5% | 31.3% | 41.7% | 43.7% | – | – | – | – | – | |
| 28.7% | 33.1% | 38.0% | 29.3% | 26.7% | 18.9% | 21.5% | 23.4% | 23.9% | 27.3% | 24.0% | 24.1% | |
| 22.9% | 32.4% | 37.3% | 28.7% | 26.2% | 18.3% | 21.0% | 22.8% | 22.1% | 26.0% | 20.9% | 21.9% | |
| 16.1% | 17.6% | 16.2% | 9.7% | 5.0% | 0.4% | 0.4% | 0.6% | 1.4% | 1.9% | 2.7% | 3.0% | |
| 5.9% | 13.9% | 19.8% | 17.7% | 20.2% | 16.6% | 19.3% | 20.8% | 20.6% | 24.0% | 18.0% | 18.9% | |
| 3.8% | – | – | – | – | – | – | – | – | – | – | – | |
| 71.3% | 66.9% | 62.0% | 70.7% | 73.3% | 81.1% | 78.5% | 76.6% | 76.1% | 72.7% | 76.0% | 75.9% | |
| -179.6% | -212.3% | -282.0% | -270.3% | -291.6% | -412.3% | -457.2% | -523.6% | -610.9% | -646.2% | -830.6% | -803.6% | |
| 28.7% | 31.5% | 38.5% | 36.8% | 38.2% | 56.3% | 59.5% | 61.8% | 79.7% | 82.2% | 103.0% | 99.5% |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.